Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06506955 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

StatusActive, Not Recruiting
PhasePhase 2/3
Started2024-10-01
View on ClinicalTrials.gov ↗

Amendment history

2026-07-27
Study Status v8
Trial status changed: Enrolling by Invitation → Active, Not Recruiting
2026-05-27
2 amendments v6-v7
2 re-verifications since 2026-04-02, no change to tracked fields
2026-03-09
Study Status v5
Primary completion date2026-12-31→2027-04
Completion date2026-12-31→2027-04-30
2025-06-30
Study Status, Contacts/Locations v4
Study sites8→9
2025-01-05
Study Status, Contacts/Locations v3
Study sites1→8
Show 2 earlier versions
2024-10-30
Study Status v2
Start dateestimated 2024-09-16→confirmed 2024-10-01
2024-08-30
Not Yet Recruiting→Enrolling by Invitation Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Enrolling by Invitation
Start date2024-07→2024-09-16
Study sites0→1
2024-07-09
Original filing
This is a nonrandomized, open-label, multicenter rollover study for patients who received futibatinib as monotherapy or as combination therapy in a Taiho-sponsored futibatinib study.
Trial Details
NCT Number NCT06506955
Lead Sponsor Taiho Oncology, Inc.
Conditions Advanced/Metastatic Cancer
Enrollment 15 participants
Start Date 2024-10-01
Primary Completion 2027-04 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-28